Features | Partner Sites | Information | LinkXpress
Sign In
BioConferenceLive
GLOBETECH PUBLISHING
JIB

New Kit Enables Rapid PCR on Whole Blood Samples

By BiotechDaily International staff writers
Posted on 02 Dec 2013
A new kit is now available that allows biotech and other life science researchers to easily perform PCR (polymerase chain reaction) analyses on whole blood samples.

The Bioline (London, United Kingdom) MyTaq Blood-PCR Kit was specifically engineered to overcome PCR inhibitors typically present in blood samples such as anticoagulants (EDTA, citrate, and heparin) and to give significantly increased sensitivity and success rates even with demanding applications such as GC-rich templates or longer amplicons.

The MyTaq Blood-PCR Kit enables very fast and highly specific direct PCR from a wide range of human and animal whole blood samples. Its novel buffer system eliminates the need for complicated extraction or purification steps or use of additives.

The advanced formulation of the MyTaq Blood-PCR Kit allows fast cycling conditions to be used, without compromising PCR specificity or yield. The addition of an inert red dye in the mix also helps improve throughput. The kit's speed and high specificity make it ideal for multiplex PCR and high-throughput genotyping assays.

Marco Calzavara, president of Bioline, said, "With MyTaq Blood-PCR Kit, researchers can now quickly and easily achieve the purity and yield necessary for high-performance PCR direct from mammalian blood samples. This makes MyTaq Blood-PCR Kit the perfect complement to our widely used PCR reagents.”

Bioline is a wholly owned subsidiary of Meridian Life Science, Inc. (Cincinnati, OH, USA).

Richard L. Eberly, president of Meridian Life Science, Inc., said, "We are delighted to release the MyTaq Blood-PCR Kit which simplifies the process of PCR extractions from whole blood samples. We are committed to our life science customers and to bringing innovation and quality products; such as the MyTaq Blood-PCR Kits to the research laboratory, clinical diagnostic laboratories, and biotechnology companies."

Related Links:

Bioline
Meridian Life Science, Inc.



comments powered by Disqus

Channels

Genomics/Proteomics

view channel
Image: Microcomputed tomography images (top) and histology images (bottom) of the knees of mice fed a very high fat diet containing omega-3 fatty acid supplement (left) or only omega-6 fatty acids (right) after a knee injury. The omega-6 diet showed abnormal bone remodeling and calcified tissue formation in the joint (white arrow). The omega-6 diet also showed significant loss of cartilage (red staining, yellow arrowhead) and increased joint inflammation (Photo courtesy of Duke University).

Dietary Omega-3 Fatty Acids Moderate Severity of Osteoarthritis in a Mouse Model

Researchers working with an osteoarthritis (OA) obese mouse model found that the fat content of the animals' diet contributed more to the development or arrest of OA than did body weight.... Read more

Drug Discovery

view channel
Image: Molecular rendering of the crystal structure of parkin (Photo courtesy of Wikimedia Commons).

Cinnamon Feeding Blocks Development of Parkinson's Disease in Mouse Model

A team of neurological researchers has identified a molecular mechanism by which cinnamon acts to protect neurons from damage caused by Parkinson's disease (PD) in a mouse model of the syndrome.... Read more

Therapeutics

view channel

Vaccine Being Developed for Heart Disease Close to Reality

The world’s first vaccine for heart disease is becoming a possibility with researchers demonstrating significant arterial plaque reduction in concept testing in mice. Klaus Ley, MD, from the La Jolla Institute for Allergy and Immunology (LA Jolla, CA, USA), and a vascular immunology specialist, is leading the vaccine... Read more

Business

view channel

A Surge in IPOs Revitalize Investments for the Global Pharma and Biotech

Anti-infective drugs, oncology, and pharmaceutical contract laboratories attract the most investment up to now. The intensified private equity and venture capital (PEVC) deal activity in the global healthcare industry during the recession years, 2008–2010, witnessed a waning post-2010. However, the decline in deals... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.